Neumann G, Niv Y, Bat L, Abramowich D, Shemesh E
Gastroenterology Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Isr J Med Sci. 1989 Apr;25(4):189-92.
A 3-week open trial of rectal hydrocortisone acetate foam (Colifoam, Stafford Miller, UK) was conducted in 19 patients with active, nonspecific distal proctocolitis. Complete or near complete remission was observed in nine patients (47.4%). Absorption of hydrocortisone acetate from Colifoam was evaluated in 13 patients by measuring early morning serum cortisol before treatment and 12 and 36 h after the final dose. Normal cortisol values were observed in every instance, suggesting that the steroid component of Colifoam was not significantly absorbed. Colifoam seems to be an effective remedy for distal proctocolitis. Its specific advantages include ease of retention and apparent nonabsorption of the active component.
对19例活动性非特异性远端直肠结肠炎患者进行了为期3周的醋酸氢化可的松直肠泡沫剂（Colifoam，英国斯塔福德·米勒公司生产）开放试验。9例患者（47.4%）实现了完全或接近完全缓解。通过测量治疗前及最后一剂后12小时和36小时的清晨血清皮质醇，对13例患者的Colifoam中醋酸氢化可的松的吸收情况进行了评估。每次均观察到皮质醇值正常，这表明Colifoam中的类固醇成分未被显著吸收。Colifoam似乎是治疗远端直肠结肠炎的一种有效药物。其具体优点包括易于保留且活性成分明显不被吸收。
